Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 17, 2017. The report discloses the granting of conditional share awards to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP). The awards were granted on February 15, 2017, with a performance period spanning three financial years from January 1, 2017, to December 31, 2019.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation transactions. Key transactional data points include:
- Share Price (GBP): £15.770 per Ordinary Share.
- Share Price (USD): $40.110 per American Depositary Share (ADS).
- Transaction Date: February 15, 2017.
- Instrument Types: Ordinary Shares (ISIN: GB0009252882) and ADSs (ISIN: US37733W1053).
Material Changes and Transaction Details
The filing details the grant of Deferred Bonus Awards and Matching Awards to 14 senior executives. The Matching Award is a one-for-one match of the Deferred Bonus Award, contingent on performance targets. Notable exceptions include:
- Sir Andrew Witty (CEO): Received a Deferred Bonus Award of 34,353 shares but is ineligible for a Matching Award due to his scheduled retirement on March 31, 2017.
- Dr. M M Slaoui (Chairman, Global Vaccines): Received a Deferred Bonus Award of 10,760 ADSs but is ineligible for a Matching Award due to his scheduled retirement on June 30, 2017.
- Ms. E Walmsley (CEO Designate): Received both Deferred and Matching Awards totaling 63,890 shares.
For all other participants, the awards consist of both Deferred and Matching components, with the total volume varying by individual.
Guidance, Outlook, and Risks
Performance Measures: Specific performance measures for the awards will be confirmed later in the year following shareholder approval of the Remuneration Policy at the Annual General Meeting (AGM) on May 4, 2017.
Vesting Conditions: The vesting date is the later of the date the Remuneration Committee determines performance achievement, the third anniversary of the Award Date, or a later date determined by the Committee.
Contingencies: The actual payout is contingent on performance over the three-year period. The amounts listed represent the maximum payable exclusive of dividend reinvestment. Progress against targets will be reported annually in the Company's Annual Report.
Investor Verification Checklist
- Verify the specific performance metrics approved at the AGM on May 4, 2017, which determine the vesting of these awards.
- Monitor the Annual Reports for progress updates on the performance targets for the 2017-2019 period.
- Confirm the final vesting status of awards for retiring executives (Sir Andrew Witty and Dr. M M Slaoui) given their departure dates.
- Review the Remuneration Policy to understand the criteria for the one-for-one Matching Award eligibility.